Decyzje ekonomiczne w świetle etyki – studium przypadków

• Authors: Chmielewska Małgorzata , Hermanowski Tomasz

Title variants

EN

Past and present economic choices from the perspective of ethics – a case study

• Languages of publication: PL EN

Abstracts

EN

By adopting an empirical and rational approach, this article investigates the influence of ethics on decision-taking in business based on case studies dating back to 50 years ago. It contrasts theoretical principles of ethics and the actual market activities of businesses by taking a closer look at two ethically controversial events from the automotive and pharmaceutical industry where human life and health was at risk. The foregoing analysis demonstrates that, where profit maximisation is at stake, businesses are prompted to take advantage of imprecise laws or absence of legal provisions, and manipulate data to protect its interests at the expense of product liability and consumer/patient safety.

Keywords

EN

business ethics; corporate culture; organizational behavior; Corporate Social Responsibility

• Publisher: Wydawnictwo Uniwersytetu Ekonomicznego we Wrocławiu
• Journal: Społeczeństwo i Ekonomia
• Year: 2015
• Issue: 2(4)
• Pages: 24-48

Contributors

author

Chmielewska Małgorzata

author

Hermanowski Tomasz

References

• Adjusting for ticket price inflation, http://www.boxofficemojo.com/about/adjuster.htm?ref=binfind.com/web (2.08.2015).
• Berenson A., Harris G., Meier B., Pollack A., Despite warnings, drug giant took long path to Vioxx recall, New York Times 2004, www.nytimes.com (27.12.2007).
• Brzozowski P., Wzorcowa hierarchia wartości, Wydawnictwo Uniwersytetu Marii Curie-Skłodowskiej, Lublin 2007.
• Cavusgil E., Merck and Vioxx: An examination of an ethical decision-making model, Journal of Business Ethics 2007, vol. 76, no. 4, s. 451–461.
• Crane A., Memory as a moral decision: The role of ethics in organization culture, Business and Society 2004, vol. 43 no. 1, s. 115–119.
• Did the FDA work with Vioxx?, http://www.The-health-gazette.com (13.12.2007).
• Dietl J., Etyka biznesu, Wydawnictwo Naukowe PWN, Warszawa 2002.
• Dowie M., Pinto madness, Mother Jones 1977, September, http://www.motherjones.com/politics/1977/09/pinto-madness?page=1.
• Dupuy R.E., Dupuy T.N., The Harper Encyclopedia of Military History from 3500 B.C. to the Present, HarperCollins, New York 1993.
• FDA, Sequence of Events with VIOXX, since Opening of IND, 2005, http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_04_E-FDA-TAB-C.htm (12.04.2015).
• Gasparski W., Etyka biznesu w działaniu, Wydawnictwo Naukowe PWN, Warszawa 2001.
• Gasparski W., Wykłady z etyki biznesu, Wydawnictwo WPISZ, Warszawa 2007.
• Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., Ray W.A., Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study, Lancet 2005, vol. 365, s. 475–481.
• Hoffman W.M., 1982, Case Study The Ford Pinto. Corporate Obligation and Responsibilities: Everything Old Is New Again, http://businessethics.qwriting.qc.cuny.edu/files/2012/01/HoffmanPinto.pdf.
• Hołówka J., Etyka w działaniu, Prószyński i S-ka, Warszawa 2001, 2002.
• Jan Paweł II, Centesimus Annus, [w:] tegoż, Dzieła zebrane, t. I: Encykliki, Wydawnictwo M, Kraków 2006.
• Jan Paweł II, Evangelium Vitae, [w:] tegoż, Dzieła zebrane, t. I: Encykliki, Wydawnictwo M, Kraków 2006.
• Kietliński K., Martinez Reyes V., Oleksyn T., Etyka w biznesie i zarządzaniu, Oficyna Ekonomiczna, Kraków 2005.
• Krumholz H.M., Ross J.S., Presler A.H., Egilman D.S., What have we learnt from Vioxx?, BMJ 2007, vol. 334, no. 7585, s. 120–123.
• Leggett C., The Ford Pinto case: The valuation of life as it applies to the negligence-efficiency argument, Law and Valuation Papers, 1999,.
• Loudon M., 2005, The FDA exposed: An interview with Dr. David Graham, the Vioxx whistleblower, Natural News 2005, http://www.vioxxnews.com (5.04.2012).
• Manoria P., Manoria P.C., COX-2 inhibitors and heart, Indian Heart Journal 2005, vol. 57, no. 6, s. 772–777, http://www.indianheartjournal.com (21.11.2007).
• Maundrell R., Evaluating risk in business ethics case studies, Teaching Business Ethics 2003, vol. 7, s. 171–178.
• Mąka W., Analiza ryzyka, Wykład II, Projektowanie sieci komputerowych, Projekt PJWSTK, materiały wykładowe dofinansowane z EFS, 2006, http://edu.pjwstk.edu.pl/wyklady/psk/scb/index.html.
• McGettigan P., Henry D., Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2, JAMA 2006, vol. 296, no. 13, s. 1633–1644.
• Najder-Stefaniak K., Wstęp do etyki biznesu, Wydawnictwo SGGW, Warszawa 2007.
• Napoli M., 2004, A Benefit/Risk Analysis of Chronic Vioxx Use: Trading an Ulcer for a Heart Attack, HealthFacts, vol. 29, no. 12, https://ssl.wum.edu.pl/docview/211611427/fulltextPDF/CEFB4BB0A8AA4CA9PQ/,DanaInfo=.asfcugmFwzx05q57Os54S9A-BG3GIb-4GXgSRKkEEWoTQ+1?accountid=48118.
• Noroian G., Cyclo-oxygenase-2 inhibitors and the kidney: A case for caution, Drug Safety 2002, vol. 25, no. 3, s. 165–172.
• O’Rourke IV J.S., Merck & Co. Inc.: Communication lessons from the withdrawal of Vioxx, Journal of Business Strategy 2006, vol. 27 no. 4, s. 11–22.
• Salij J., Czy etyka religijna jest interesowna?, [w:] tegoż, Szukającym drogi, Wydawnictwo Polskiej Prowincji Dominikanów, Poznań 1993.
• Snihur S., Etyka biznesu, Wydawnictwo SGGW, Warszawa 2006.
• Ślęczek-Czakon D., Problem wartości i jakości życia w sporach bioetycznych, Wydawnictwo Uniwersytetu Śląskiego, Katowice 2004.
• Tong C.H., Tong L.I., Tong J.E., The Vioxx recall case and comments, Competitiveness Review: An International Business Journal 2009, vol. 19, no. 2, s. 114–118.
• Topol E.J., Failing the public health – Rofecoxib, Merck, and the FDA, New England Journal of Medicine 2004, vol. 351, no. 17, s. 1707–1709.
• Vioxx: Lessons for Health Canada and the FDA, CMAJ 2005, vol. 172, no. 1, s. 1.